THE ARISING · Markets & Strategy
Parkinson's Stem Cell Developer Aspen Neuroscience Files for Nasdaq IPO
Aspen Neuroscience, a San Diego company that makes a Parkinson's cell therapy from a patient's own skin cells, has filed publicly for a Nasdaq IPO, according to Renaissance Capital. The therapy, sasineprocel, is investigational and not approved or available outside clinical trials.
The company filed on October 9, 2026, after a confidential submission on March 30, 2026. It plans to trade under the ticker ASPE. Renaissance Capital estimates the deal at up to $100 million. Leerink Partners, Piper Sandler and Stifel are the bookrunners.
Aspen's lead product is sasineprocel. According to the source, it is a single-dose therapy designed to replace the dopamine-producing neurons lost in Parkinson's disease. It is made from the patient's own cells.
The product holds two FDA designations, RMAT and Fast Track, according to the source. As of August 18, 2026, 15 patients had been dosed in an open-label Phase 1/2a trial. Open-label means patients and doctors know what is being given.
The company says that, after FDA feedback, it expects to dose its first Phase 3 patients in the second half of 2027. Renaissance Capital lists Aspen as founded in 2018, with about 120 employees.
For investors, the offering is a direct test of appetite for a regenerative approach in an age-related neurodegenerative disease. The company is selling shares with only 15 patients dosed and a pivotal trial still ahead. The size of the raise, the pricing and the demand will show how much weight the market gives to early data and regulatory designations at this stage. Those outcomes are not yet known.
What to watch next
Whether Aspen sets a price range and completes the listing, and what FDA feedback means for its Phase 3 timing.
England and Wales Mortality Hits Record Nine-Month Low, Pressuring Annuity Pricing Parkinson's Stem Cell Developer Aspen Neuroscience Files for Nasdaq IPO IMF Says AI Productivity Gains Could Outweigh Asia's Aging-Driven Workforce Decline UCSF Details How FDA's Bone Density Endpoint Will Shrink Osteoporosis Trials Tiny Health Raises $33 Million Series B as Adult Microbiome Testing Overtakes Pediatric